DNAprint Genomics (DNAG)

[worktoplay]

Who was it that said DNAP doesn't do Whole Genome Analyses?

Ramona Coopersotck, Ph.D. | Manager, Genotyping Services

Dr. Cooperstock completed her B.Sc. in Biochemistry at the University of Victoria. She completed her Ph.D. at the University of Toronto on RNA regulation during Drosophila embryonic development. She was a Research Associate at the University of Toronto where she developed a functional genomics project for the model organism C. elegans. Dr. Cooperstock has an extensive background in Molecular Biology and Genomics as well as in project development and management. Dr. Cooperstock joined Ellipsis in January 2006. Her broad experience and skills in molecular biology are a critical asset to advising, designing and interpreting our clients' genotyping and related service needs. She was recently responsible for the successful launch of our new services in whole genome genotyping analyses and expression.

http://www.ellipsisbio.com/services/index.html

http://www.ellipsisbio.com/Ellipsis%20Fact%20Sheet.pdf

It would appear there have been a few updates to the Ellipsis Biotherapeutics website, as well as a few personnel additions.

BTW, and this the first I've seen it confirmed, but if you peruse the site you will find that the intellectual property portfolio in Crohn's disease was part of what DNAPrint acquired in the Ellipsis deal. It's actually stated in Rubin's bio for anyone interested.

This is just FYI. As always, do your own Due Diligence and make your own investment decisions.

Later,
W2P